LASCCO
LASCCO specializes in developing diagnostic tests for sepsis, notably the Pancreatic Stone Protein (PSP) test, which accelerates the recognition of sepsis. The company has licensed the PSP commercial rights to Abionic SA, which has received FDA clearance and EU certification for its IVD CAPSULE PSP test. LASCCO has also entered into a strategic partnership with Fapon to bring the PSP solution to China, aiming to improve early detection and treatment of sepsis worldwide.
Industries
Nr. of Employees
Very Large (1000+)
Patents
Products
PSP biomarker diagnostic test
A diagnostic test based on Pancreatic Stone Protein (PSP) intended to detect and monitor sepsis risk; designed for rapid results from small-volume blood samples and adaptable to point-of-care and laboratory analyzer platforms.
PSP biomarker diagnostic test
A diagnostic test based on Pancreatic Stone Protein (PSP) intended to detect and monitor sepsis risk; designed for rapid results from small-volume blood samples and adaptable to point-of-care and laboratory analyzer platforms.
Services
Negotiation and management of licensing agreements and strategic partnerships to enable commercialization and regional deployment of PSP-based diagnostics.
Negotiation and management of licensing agreements and strategic partnerships to enable commercialization and regional deployment of PSP-based diagnostics.
Expertise Areas
- Sepsis biomarker diagnostics
- Point-of-care assay development
- Immunoassay integration for laboratory analyzers
- Clinical diagnostic validation and evidence generation
Key Technologies
- Biomarker-based diagnostics
- Rapid immunoassay for capillary blood
- Chemiluminescent immunoassay (CLIA) integration
- Point-of-care diagnostic platforms
News & Updates
On October 2, 2024, Abionic’s IVD CAPSULE PSP test received 510(k) clearance from the U.S. Food and Drug Administration to accelerate the time-to-detection of sepsis.
On October 26, 2023, LASCCO and Abionic announced a licensing agreement with Fapon to bring the PSP sepsis test to China.
Over 80 peer-reviewed publications support the clinical efficacy of PSP in early sepsis detection, including its use at admission to intensive care, serial measurements in ICU, and predicting sepsis in severely burned patients.
Research articles highlight the use of PSP for early detection of sepsis in ICU settings through serial measurements.
Studies show that PSP can predict sepsis in severely burned patients, aiding in timely intervention.
On October 2, 2024, Abionic’s IVD CAPSULE PSP test received 510(k) clearance from the U.S. Food and Drug Administration to accelerate the time-to-detection of sepsis.
On October 26, 2023, LASCCO and Abionic announced a licensing agreement with Fapon to bring the PSP sepsis test to China.
Over 80 peer-reviewed publications support the clinical efficacy of PSP in early sepsis detection, including its use at admission to intensive care, serial measurements in ICU, and predicting sepsis in severely burned patients.
Research articles highlight the use of PSP for early detection of sepsis in ICU settings through serial measurements.
Studies show that PSP can predict sepsis in severely burned patients, aiding in timely intervention.